398 related articles for article (PubMed ID: 1873773)
1. A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors.
Casper ES; Gaynor JJ; Hajdu SI; Magill GB; Tan C; Friedrich C; Brennan MF
Cancer; 1991 Sep; 68(6):1221-9. PubMed ID: 1873773
[TBL] [Abstract][Full Text] [Related]
2. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study.
Zalupski M; Metch B; Balcerzak S; Fletcher WS; Chapman R; Bonnet JD; Weiss GR; Ryan J; Benjamin RS; Baker LH
J Natl Cancer Inst; 1991 Jul; 83(13):926-32. PubMed ID: 2067035
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma--reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Bramwell V; Rouesse J; Steward W; Santoro A; Schraffordt-Koops H; Buesa J; Ruka W; Priario J; Wagener T; Burgers M
J Clin Oncol; 1994 Jun; 12(6):1137-49. PubMed ID: 8201375
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant chemotherapy with doxorubicin in high-grade soft tissue sarcoma: a randomized trial of the Scandinavian Sarcoma Group.
Alvegård TA; Sigurdsson H; Mouridsen H; Solheim O; Unsgaard B; Ringborg U; Dahl O; Nordentoft AM; Blomqvist C; Rydholm A
J Clin Oncol; 1989 Oct; 7(10):1504-13. PubMed ID: 2674336
[TBL] [Abstract][Full Text] [Related]
5. Detection of doxorubicin cardiotoxicity in patients with sarcomas by indium-111-antimyosin monoclonal antibody studies.
Carrió I; Lopez-Pousa A; Estorch M; Duncker D; Berná L; Torres G; de Andrés L
J Nucl Med; 1993 Sep; 34(9):1503-7. PubMed ID: 8355070
[TBL] [Abstract][Full Text] [Related]
6. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
Lorigan P; Verweij J; Papai Z; Rodenhuis S; Le Cesne A; Leahy MG; Radford JA; Van Glabbeke MM; Kirkpatrick A; Hogendoorn PC; Blay JY;
J Clin Oncol; 2007 Jul; 25(21):3144-50. PubMed ID: 17634494
[TBL] [Abstract][Full Text] [Related]
7. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT;
Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant chemotherapy for patients with soft tissue sarcoma.
Ozaki T; Sugihara S; Hamada M; Nakagawa Y; Inoue H
Hiroshima J Med Sci; 1993 Sep; 42(3):109-15. PubMed ID: 8253605
[TBL] [Abstract][Full Text] [Related]
9. Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breast.
Speyer JL; Green MD; Dubin N; Blum RH; Wernz JC; Roses D; Sanger J; Muggia FM
Am J Med; 1985 Apr; 78(4):555-63. PubMed ID: 3838618
[TBL] [Abstract][Full Text] [Related]
10. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin.
Wexler LH; Andrich MP; Venzon D; Berg SL; Weaver-McClure L; Chen CC; Dilsizian V; Avila N; Jarosinski P; Balis FM; Poplack DG; Horowitz ME
J Clin Oncol; 1996 Feb; 14(2):362-72. PubMed ID: 8636745
[TBL] [Abstract][Full Text] [Related]
11. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy.
Elias A; Ryan L; Sulkes A; Collins J; Aisner J; Antman KH
J Clin Oncol; 1989 Sep; 7(9):1208-16. PubMed ID: 2504890
[TBL] [Abstract][Full Text] [Related]
12. Ten-year follow-up results of perioperative chemotherapy with doxorubicin and ifosfamide for high-grade soft-tissue sarcoma of the extremities: Japan Clinical Oncology Group study JCOG0304.
Tanaka K; Mizusawa J; Naka N; Kawai A; Katagiri H; Hiruma T; Matsumoto Y; Tsuchiya H; Nakayama R; Hatano H; Emori M; Watanuki M; Yoshida Y; Okamoto T; Abe S; Asanuma K; Yokoyama R; Hiraga H; Yonemoto T; Morii T; Ae K; Nagano A; Yoshikawa H; Fukuda H; Ozaki T; Iwamoto Y
BMC Cancer; 2019 Sep; 19(1):890. PubMed ID: 31492159
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant chemotherapy for patients with high-grade soft-tissue sarcomas of the extremity.
Chang AE; Kinsella T; Glatstein E; Baker AR; Sindelar WF; Lotze MT; Danforth DN; Sugarbaker PH; Lack EE; Steinberg SM
J Clin Oncol; 1988 Sep; 6(9):1491-500. PubMed ID: 3047339
[TBL] [Abstract][Full Text] [Related]
14. Treatment of soft tissue sarcoma in childhood and adolescence. A report of the German Cooperative Soft Tissue Sarcoma Study.
Koscielniak E; Jürgens H; Winkler K; Bürger D; Herbst M; Keim M; Bernhard G; Treuner J
Cancer; 1992 Nov; 70(10):2557-67. PubMed ID: 1482503
[TBL] [Abstract][Full Text] [Related]
15. Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma.
Hortobagyi GN; Frye D; Buzdar AU; Ewer MS; Fraschini G; Hug V; Ames F; Montague E; Carrasco CH; Mackay B
Cancer; 1989 Jan; 63(1):37-45. PubMed ID: 2910423
[TBL] [Abstract][Full Text] [Related]
16. [Responses of 109 adult soft tissue sarcoma patients to chemotherapy].
Qiu MZ; Xu F; Wang SS; Luo HY; Wang F; Li FH; Sun XF; Xu GC; Lin TY; Huang HQ; Jiang WQ; Guan ZZ; Xu RH
Ai Zheng; 2007 Dec; 26(12):1344-9. PubMed ID: 18076798
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of soft tissue sarcomas in childhood and adolescence: results of the CWS-81 multicenter therapy study].
Koscielniak E; Treuner J; Jürgens H; Winkler K; Bürger D; Herbst M; Ritter J; Niethammer D; Müller-Weihrich S; Bernhard G
Klin Padiatr; 1991; 203(4):211-9. PubMed ID: 1942928
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Santoro A; Tursz T; Mouridsen H; Verweij J; Steward W; Somers R; Buesa J; Casali P; Spooner D; Rankin E
J Clin Oncol; 1995 Jul; 13(7):1537-45. PubMed ID: 7602342
[TBL] [Abstract][Full Text] [Related]
19. Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial.
Le Cesne A; Blay JY; Domont J; Tresch-Bruneel E; Chevreau C; Bertucci F; Delcambre C; Saada-Bouzid E; Piperno-Neumann S; Bay JO; Mir O; Ray-Coquard I; Ryckewaert T; Valentin T; Isambert N; Italiano A; Clisant S; Penel N
Lancet Oncol; 2015 Mar; 16(3):312-9. PubMed ID: 25680558
[TBL] [Abstract][Full Text] [Related]
20. Preoperative and postoperative adjuvant combination chemotherapy for adults with high grade soft tissue sarcoma.
Casper ES; Gaynor JJ; Harrison LB; Panicek DM; Hajdu SI; Brennan MF
Cancer; 1994 Mar; 73(6):1644-51. PubMed ID: 8156491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]